Squarepoint
PRME icon

Squarepoint’s Prime Medicine PRME Stock Holding History

Squarepoint’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$327K Sell
94,066
-123,976
-57% -$472K ﹤0.01% 3642
2025
Q4 		$757K Buy
218,042
+178,441
+451% +$794K ﹤0.01% 2852
2025
Q3 		$219K Buy
39,601
+3,775
+11% +$15.3K ﹤0.01% 3885
2025
Q2 		$88.5K Buy
+35,826
New +$55.2K ﹤0.01% 4201
2024
Q4 		– Sell
-124,369
Closed -$481K – 5405
2024
Q3 		$481K Buy
124,369
+60,908
+96% +$282K ﹤0.01% 3125
2024
Q2 		$326K Buy
63,461
+3,895
+7% +$23.6K ﹤0.01% 3381
2024
Q1 		$417K Sell
59,566
-11,957
-17% -$90.7K ﹤0.01% 3181
2023
Q4 		$634K Buy
71,523
+56,033
+362% +$432K ﹤0.01% 2839
2023
Q3 		$148K Buy
+15,490
New +$201K ﹤0.01% 3494

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Squarepoint's PRME Position: Q1 2026 in Review

Squarepoint reduced its Prime Medicine (PRME) stake by 57% in Q1 2026, selling an estimated $472K and leaving 94,066 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #3642.

Squarepoint first reported a position in PRME in Q3 2023 and has held it in 9 quarters since. The position peaked at $757K in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Squarepoint held 94,066 shares of Prime Medicine worth $327K as of Q1 2026.
  • Squarepoint sold 123,976 Prime Medicine shares in Q1 2026, an estimated $472K.
  • Prime Medicine made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3642 holding.
  • Squarepoint first reported a position in Prime Medicine in Q3 2023 and has held it in 9 quarters since.
  • Squarepoint's Prime Medicine position peaked at $757K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.